These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 19650075)

  • 1. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. I. Class III beta-tubulin.
    Katsetos CD; Dráberová E; Legido A; Dumontet C; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):505-13. PubMed ID: 19650075
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tubulin targets in the pathobiology and therapy of glioblastoma multiforme. II. gamma-Tubulin.
    Katsetos CD; Dráberová E; Legido A; Dráber P
    J Cell Physiol; 2009 Dec; 221(3):514-20. PubMed ID: 19650077
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting βIII-tubulin in glioblastoma multiforme: from cell biology and histopathology to cancer therapeutics.
    Katsetos CD; Draber P; Kavallaris M
    Anticancer Agents Med Chem; 2011 Oct; 11(8):719-28. PubMed ID: 21707498
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Class III beta-tubulin in human development and cancer.
    Katsetos CD; Herman MM; Mörk SJ
    Cell Motil Cytoskeleton; 2003 Jun; 55(2):77-96. PubMed ID: 12740870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EGF receptor inhibitors in the treatment of glioblastoma multiform: old clinical allies and newly emerging therapeutic concepts.
    Gadji M; Crous AM; Fortin D; Krcek J; Torchia M; Mai S; Drouin R; Klonisch T
    Eur J Pharmacol; 2009 Dec; 625(1-3):23-30. PubMed ID: 19836372
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Microtubules: a dynamic target in cancer therapy.
    Pasquier E; Kavallaris M
    IUBMB Life; 2008 Mar; 60(3):165-70. PubMed ID: 18380008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Designer therapies for glioblastoma multiforme.
    Sathornsumetee S; Rich JN
    Ann N Y Acad Sci; 2008 Oct; 1142():108-32. PubMed ID: 18990124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Altered cellular distribution and subcellular sorting of gamma-tubulin in diffuse astrocytic gliomas and human glioblastoma cell lines.
    Katsetos CD; Reddy G; Dráberová E; Smejkalová B; Del Valle L; Ashraf Q; Tadevosyan A; Yelin K; Maraziotis T; Mishra OP; Mörk S; Legido A; Nissanov J; Baas PW; de Chadarévian JP; Dráber P
    J Neuropathol Exp Neurol; 2006 May; 65(5):465-77. PubMed ID: 16772870
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Class III beta-tubulin and gamma-tubulin are co-expressed and form complexes in human glioblastoma cells.
    Katsetos CD; Dráberová E; Smejkalová B; Reddy G; Bertrand L; de Chadarévian JP; Legido A; Nissanov J; Baas PW; Dráber P
    Neurochem Res; 2007 Aug; 32(8):1387-98. PubMed ID: 17406983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Class III b-tubulin overexpression in gynecologic tumors: implications for the choice of microtubule targeted agents?
    English DP; Roque DM; Santin AD
    Expert Rev Anticancer Ther; 2013 Jan; 13(1):63-74. PubMed ID: 23259428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging microtubule targets in glioma therapy.
    Katsetos CD; Reginato MJ; Baas PW; D'Agostino L; Legido A; Tuszyn Ski JA; Dráberová E; Dráber P
    Semin Pediatr Neurol; 2015 Mar; 22(1):49-72. PubMed ID: 25976261
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Beyond grade: molecular pathology of malignant gliomas.
    Sulman EP; Guerrero M; Aldape K
    Semin Radiat Oncol; 2009 Jul; 19(3):142-9. PubMed ID: 19464628
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Molecular markers of extracellular matrix remodeling in glioblastoma vessels: microarray study of laser-captured glioblastoma vessels.
    Pen A; Moreno MJ; Martin J; Stanimirovic DB
    Glia; 2007 Apr; 55(6):559-72. PubMed ID: 17266141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Brain tumor stem cells as research and treatment targets.
    Hide T; Takezaki T; Nakamura H; Kuratsu J; Kondo T
    Brain Tumor Pathol; 2008; 25(2):67-72. PubMed ID: 18987831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Update on tubulin-binding agents.
    Attard G; Greystoke A; Kaye S; De Bono J
    Pathol Biol (Paris); 2006 Mar; 54(2):72-84. PubMed ID: 16545633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. βIII-tubulin enhances efficacy of cabazitaxel as compared with docetaxel.
    Smiyun G; Azarenko O; Miller H; Rifkind A; LaPointe NE; Wilson L; Jordan MA
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):151-164. PubMed ID: 28567478
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Class III β-tubulin and the cytoskeletal gateway for drug resistance in ovarian cancer.
    De Donato M; Mariani M; Petrella L; Martinelli E; Zannoni GF; Vellone V; Ferrandina G; Shahabi S; Scambia G; Ferlini C
    J Cell Physiol; 2012 Mar; 227(3):1034-41. PubMed ID: 21520077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. 15-Deoxi-Delta(12,14)-prostaglandin J2 is a tubulin-binding agent that destabilizes microtubules and induces mitotic arrest.
    Cocca C; Dorado J; Calvo E; López JA; Santos A; Perez-Castillo A
    Biochem Pharmacol; 2009 Nov; 78(10):1330-9. PubMed ID: 19576185
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tubulin and microtubules as targets for anticancer drugs.
    Hadfield JA; Ducki S; Hirst N; McGown AT
    Prog Cell Cycle Res; 2003; 5():309-25. PubMed ID: 14593726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. βIII-Tubulin is required for interphase microtubule dynamics in untransformed human mammary epithelial cells.
    Bouchet BP; Puisieux A; Galmarini CM
    Eur J Cell Biol; 2011 Oct; 90(10):872-8. PubMed ID: 21820201
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.